CASE REPORT

Prolonged remission after long-term treatment with steroidogenesis inhibitors in Cushing’s syndrome caused by ectopic ACTH secretion

S T Sharma and L K Nieman
Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Building 10, CRC, 1 East, Rm 3140, Bethesda, Maryland 20892-1109, USA

(Correspondence should be addressed to L K Nieman; Email: niemanl@nih.gov; S T Sharma; Email: sharmast@mail.nih.gov)

Abstract

Spontaneous remission is rare in ectopic ACTH syndrome (EAS). We describe four patients with presumed EAS in whom long-term treatment with steroidogenesis inhibitors was followed by prolonged remission of hypercortisolemia. Biochemical testing was consistent with EAS, but imaging failed to identify a tumor. Patients were treated with ketoconazole alone or with mitotane and/or metyrapone to control hypercortisolemia. Dexamethasone was added when a block and replace strategy was used. Treatment with steroidogenesis inhibitors for 3–10 years in these patients was followed by a prolonged period of remission (15–60 months). During remission, the first patient had an elevated ACTH, low cortisol and 24-h urinary free cortisol (UFC), and adrenal atrophy on computerized tomography scan during remission, suggesting a direct toxic effect on the adrenal glands. Cases 2 and 3 had normal to low ACTH levels and low-normal UFC, consistent with an effect at the level of the ectopic tumor. They did not have a history of cyclicity and case 3 has been in remission for 5 years, making cyclic Cushing’s syndrome less likely. Case 4, with a history of cyclic hypercortisolism, had normal to slightly elevated ACTH levels and low-normal UFC during remission. The most likely etiology of remission is cyclic production of ACTH by the ectopic tumor. Spontaneous and sustained remission of hypercortisolism is possible in EAS after long-term treatment with steroidogenesis inhibitors; a drug holiday may be warranted during chronic therapy to evaluate this. The pathophysiology remains unclear but may involve several different mechanisms.

European Journal of Endocrinology 166 531–536

Introduction

Spontaneous remission in Cushing’s syndrome is rare; most cases probably represent infarction of an ACTH-secreting pituitary adenoma (1, 2, 3, 4). Transient resolution of hypercortisolism, with inter-cyclic periods as long as 4 years, is most common in Cushing’s disease (5, 6). Few cases of sustained spontaneous remission have been documented in ectopic ACTH syndrome (EAS) (7, 8). In this article, we describe four cases of presumed EAS where a prolonged remission followed long-term treatment with steroidogenesis inhibitors. Our aim is to make readers aware of this possibility and urge them to assess intermittently for remission in patients receiving chronic treatment with these agents.

Methods

All patients had confirmation of Cushing’s syndrome and evaluation of its etiology at the initial National Institutes of Health (NIH) visit after discontinuing any steroidogenesis inhibitors for 6 weeks or more. Biochemical testing including corticotropin-releasing hormone (CRH) stimulation test, 8 mg dexamethasone suppression test (DST), and inferior petrosal sinus sampling (IPSS) was consistent with EAS. As previously reported, imaging studies (computerized tomography (CT) and magnetic resonance imaging (MRI) of neck, chest, abdomen, pelvis, and standard 6 mCi dose octreotide scan) performed every 6–12 months failed to identify a source (9) (cases 31–34). Some patients received [18F]-3,4-dihydroxyphenylalanine positron emission tomography scans, 64-slice gated cardiac CT, cardiac MRI, or an 18 mCi dose octreotide scan (9).

Case 1

A 42-year-old man presented in 1999 with weight gain, moon facies, proximal muscle weakness, easy bruising, violaceous striae, and an elevated 24-h urinary free cortisol (UFC) and ACTH. IPSS suggested an ectopic source of ACTH. Perhaps because of a 5 mm pituitary...
mass seen on MRI, the patient underwent hemihyppophysectomy at the outside institution, but hypercortisolism persisted and no tumor was seen on pathology. Another institution’s evaluation was consistent with EAS; ketoconazole was initiated when no tumor was found. At the NIH in 2003, biochemical testing was consistent with EAS and imaging did not identify a source of ectopic ACTH (Table 1). Eucortisolism was achieved initially with ketoconazole, but subsequently he required metyrapone (in 2004) and mitotane (in 2008) to maintain eucortisolism (Fig. 1A). After ketoconazole was discontinued because of liver enzyme elevations, UFC, though improved, remained elevated (100–268 μg/day and 298.1–739.7 nmol/day), and bilateral adrenalectomy was considered.

In June 2009, the patient developed clinical acute adrenal insufficiency; cortisol was 4 μg/dl (110.4 nmol/l; normal: 5–25 μg/dl, 138–690 nmol/l) with a low-normal UFC, ACTH was elevated (3.3–14.5 pmol/l). After ketoconazole was discontinued, UFC remained undetectable (5.5 nmol/day) and ACTH Z 3 pg/ml (0.7 pmol/l); imaging studies failed to identify a source of ectopic ACTH. However, the patient was not hypercortisolemic at that time (UFC = 2 μg/day (5.5 nmol/day) and ACTH = 3 pg/ml (0.7 pmol/l); Fig. 1D). After ~6 months, remission, hypercortisolism and high ACTH levels recurred, consistent with cyclic Cushing’s syndrome. For unclear reasons, the patient underwent a second unsuccessful TSS in July 2003.

The patient was then referred to the NIH. Biochemical testing including IPSS performed during hypercortisolism was consistent with EAS (Table 1). Ketoconazole was restarted after imaging studies failed to identify a source of ectopic ACTH. Over the next few years, the patient was maintained on a block and replace regimen with ketoconazole (400–1000 mg/day), cyproheptadine 16 mg/day (continued by his local physician), and low-dose dexamethasone (125 μg/day). On this regimen, UFC remained undetectable, but ACTH ranged from 15 to 66 pg/ml (3.3–14.5 pmol/l).

In June 2009, the patient developed adrenal insufficiency; ketoconazole was discontinued and mineral density. At the NIH in 2003, biochemical testing was suggestive of EAS (Table 1). CT scan showed bilateral adrenal hyperplasia. After imaging studies failed to identify the source of ACTH, ketoconazole was initiated. Metyrapone was later added along with dexamethasone using a ‘block and replace’ strategy (Fig. 1C).

In September 2006, the patient had a sub-normal ACTH level and an undetectable UFC. CT scan showed atrophic adrenal glands. Steroidogenesis inhibitors were discontinued and she was maintained on dexamethasone 250 μg daily. In September 2007, ACTH and UFC were in the low-normal range and the cortisol response to ACTH stimulation was normal; dexamethasone was discontinued. An 8 mm retrocardiac mass was noted on CT and MRI of the chest but was not resected as the patient was eucortisolemic. ACTH and UFC values remain in the low-normal range with no signs and symptoms of hypercortisolism or adrenal insufficiency as of November 2011 (Fig. 1C and Table 1).

**Case 4**

A 41-year-old man was admitted with sudden onset of altered mental status, hypertension, and hypokalemia in May 2001. Biochemical evaluation confirmed the diagnosis of ACTH-dependent Cushing’s syndrome. Imaging studies did not identify a source of ectopic ACTH secretion, but pituitary MRI showed an inferior convexity and asymmetric enlargement of the left side. IPSS suggested a pituitary source of ACTH, but hypercortisolism was not confirmed at the time of IPSS. Ketoconazole and cyproheptadine were initiated after unsuccessful transsphenoidal surgery (TSS) in October 2001, and cortisol levels decreased. A repeat IPSS performed while off all medications was consistent with a pituitary source of ACTH. However, the patient was not hypercortisolemic at that time (UFC = 2 μg/day (5.5 nmol/day) and ACTH = 3 pg/ml (0.7 pmol/l); Fig. 1D). After ~6 months, remission, hypercortisolism and high ACTH levels recurred, consistent with cyclic Cushing’s syndrome. For unclear reasons, the patient underwent a second unsuccessful TSS in July 2003.

The patient was then referred to the NIH. Biochemical testing including IPSS performed during hypercortisolism was consistent with EAS (Table 1). Ketoconazole was restarted after imaging studies failed to identify a source of ectopic ACTH. Over the next few years, the patient was maintained on a block and replace regimen with ketoconazole (400–1000 mg/day), cyproheptadine 16 mg/day (continued by his local physician), and low-dose dexamethasone (125 μg/day). On this regimen, UFC remained undetectable, but ACTH ranged from 15 to 66 pg/ml (3.3–14.5 pmol/l).
Table 1 Clinical and biochemical features of four patients with presumed ectopic ACTH syndrome. To convert ACTH level to picomoles per liter, multiply by 0.2202. To convert urinary free cortisol (UFC) level to nanomoles per day, multiply by 2.759.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at presentation (years)</td>
<td>1</td>
</tr>
<tr>
<td>Male</td>
<td>42</td>
</tr>
<tr>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Symptoms/signs</td>
<td></td>
</tr>
<tr>
<td>Weight gain, moon facies, proximal muscle weakness, easy bruising, and violaceous striae</td>
<td>110</td>
</tr>
<tr>
<td>Fatigue, apathy, weight gain, and hypertension</td>
<td>910</td>
</tr>
<tr>
<td>Truncal obesity, hirsutism, easy bruising, lower extremity edema, and hypertension</td>
<td></td>
</tr>
<tr>
<td>Altered mental status, violaceous striae, plethora, moon facies, hypertension, and hypokalemia</td>
<td></td>
</tr>
<tr>
<td>Initial labs at NIH</td>
<td></td>
</tr>
<tr>
<td>ACTH (pg/ml; normal: 9–52)</td>
<td>110</td>
</tr>
<tr>
<td>UFC (μg/day; normal: 8–77)</td>
<td>910</td>
</tr>
<tr>
<td>CRH stimulation test</td>
<td>Ectopic</td>
</tr>
<tr>
<td>HD DST</td>
<td>Not done</td>
</tr>
<tr>
<td>MRI pituitary</td>
<td>5-mm left-sided lesion</td>
</tr>
<tr>
<td>IPSS venogram</td>
<td>Normal venous anatomy</td>
</tr>
<tr>
<td>IPSS (peak ACTH IPS/P)</td>
<td>1.5 (109.7/73.6)</td>
</tr>
<tr>
<td>Anatomical imaging (CT/MRI)</td>
<td>LLL nodule</td>
</tr>
<tr>
<td>Functional imaging</td>
<td>Negative</td>
</tr>
<tr>
<td>Surgery</td>
<td>Unsuccessful hemihypophysectomy at outside facility; FP LLL nodule surgically removed → scar tissue on pathology</td>
</tr>
<tr>
<td>Last follow-up (during remission)</td>
<td></td>
</tr>
<tr>
<td>ACTH (pg/ml; normal: &lt;46)</td>
<td>242</td>
</tr>
<tr>
<td>UFC (μg/day; normal: 3.5–45)</td>
<td>13</td>
</tr>
<tr>
<td>Duration of remission (months)</td>
<td>16</td>
</tr>
<tr>
<td>Possible cause</td>
<td>Toxic effect of steroidogenesis inhibitors/mitotane on adrenal gland</td>
</tr>
</tbody>
</table>

HD DST, High dose (8 mg) dexamethasone suppression test; FP, false positive; LLL, left lower lobe; RLL, right lower lobe; CT, computed tomography; MRI, magnetic resonance imaging; IPS/P, inferior petrosal sinus to peripheral; UFC, 24-h urinary free cortisol.

*Functional imaging by low-dose octreotide scan (LOCT), high-dose octreotide scan (HOCT), and [18F]-3,4-dihydroxyphenylalanine positron emission tomography (F-DOPA-PET).
dexamethasone increased to 250 µg daily. This remission persisted for ~6 months and was followed by recurrent hypercortisolemia, and ketoconazole was reinitiated.

In June 2010, ACTH was elevated at 60 pg/ml (13.2 pmol/l) with a UFC of 12 µg/day (33.1 nmol/day). Repeat testing after discontinuation of ketoconazole confirmed an elevated ACTH and low-normal UFC. The adrenal glands were of normal size on CT scan and the patient did not have symptoms of hypercortisolism or adrenal insufficiency. An ACTH stimulation test showed borderline peak cortisol response at 17 µg/dl (469.2 nmol/l); dexamethasone was continued. In June 2011, the morning cortisol (3.5 µg/dl (96.6 nmol/l)) and UFC were low with a normal ACTH (Table 1). The cortisol response to ACTH stimulation was normal. The patient has since been maintained on hydrocortisone 10 mg daily and continues to have no signs and symptoms of recurrence as of October 2011.

Discussion

Spontaneous and sustained remission is rarely reported in EAS (7, 8). Beardwell et al. described two cases (biochemical testing consistent with EAS but a source of ectopic ACTH not identified) in which hypercortisolism resolved for up to 14 months after treatment with metyrapone. One patient had normal ACTH and cortisol levels 6 months after 2 years of treatment (maximum dose 2250 mg/day). The second patient was in remission for ~14 months after 7 months of treatment with metyrapone 3000 mg daily and prednisolone 7.5 mg daily (7). The authors hypothesized that spontaneous remission in these cases resulted from a direct effect of metyrapone on ACTH secretion from the ectopic tumor or that the tumor required high cortisol levels to secrete ACTH.

Loh et al. (8) described a case of EAS due to a pheochromocytoma in which treatment with
ketoconazole (400–600 mg/day) for 5 months was followed by spontaneous clinical and biochemical remission for 18 months until resection of the pheochromocytoma.

We describe four cases with presumed EAS where long-term treatment with steroidogenesis inhibitors was followed by remission for 15–60 months. The mechanism of remission in these cases remains unclear. We postulate that they represent a direct effect on the adrenal glands (case 1), and have effects on tumoral ACTH secretion (cases 2 and 3), and on cyclic ACTH secretion (case 4).

In the case of the first patient, treatment with steroidogenesis inhibitors for ~10 years was followed by resolution of hypercortisolemia for ~16 months (Table 1). Remission was associated with an elevated ACTH level, low UFC, and bilateral adrenal atrophy. There are few data on the long-term effects of combined treatment with ketoconazole and metyrapone on the adrenal glands and/or ACTH secretion by a tumor. Mitotane has an adrenolytic effect when given chronically at high doses (>4 g/day) and this underlies its use in the treatment of adrenal cancer (10, 11). However, the highest daily dose of mitotane used in this patient was 2 g and the duration of treatment was 1.5 years. Although mitotane levels were not measured, it is likely that mitotane, in combination with long-term treatment with ketoconazole and metyrapone, had a direct toxic effect on the adrenal glands, which was reversible after discontinuation of the treatment.

In the second case, treatment with ketoconazole for ~6 years was accompanied by gradually decreasing ACTH levels followed by spontaneous resolution of hypercortisolism. Although we do not have recent biochemical data, the patient reports no signs and symptoms of recurrence and appears to have been in clinical remission for the past 3 years. At the last biochemical evaluation, after taking no medications for 1 year, he had a high-normal ACTH, normal UFC, and decreasing hyperplasia of the adrenal glands on CT scan. The third patient had a response similar to case 2. In her case, treatment with metyrapone and ketoconazole for more than 3 years was followed by remission characterized by low ACTH and cortisol levels and bilateral adrenal atrophy. These data are consistent with effects on the tumor to decrease ACTH secretion and/or bioactivity.

As suggested previously, an ACTH-secreting tumor might require high cortisol levels for growth and/or hormone secretion (7). Mizoguchi et al. reported decreasing ACTH and cortisol levels with metyrapone treatment (1500 mg/day for 2 months) in a boy with an ACTH-producing thymic carcinoid tumor. In vitro, tumor cells showed increased proopiomelanocortin (POMC) gene expression when cultured in the presence of 1000 µg/ml of hydrocortisone (12). In another ACTH-producing thymic carcinoid, ketoconazole treatment (800 mg/day for 1 week) led to decreased ACTH and cortisol levels. In culture, ketoconazole reduced ACTH secretion from the thymic tumor cells while cortisol and CRH had no effect, suggesting a direct effect on the tumor cells (13). These cases suggest that long-term treatment with ketoconazole and/or metyrapone may decrease tumoral ACTH secretion, either directly or by decreasing hypercortisolism. It is not known whether these effects are specific to thymic carcinoids or how often they occur.

Another possible explanation for remission may be altered POMC gene expression and defective ACTH production by the ectopic tumor (14, 15, 16, 17). The tumor may dedifferentiate or develop a transcriptional or posttranscriptional defect leading to production of an ACTH molecule with reduced ability to stimulate adrenal hormonogenesis.

At daily doses of 16–24 mg, the serotonin receptor antagonist cyproheptadine was associated with decreased ACTH and cortisol levels in Cushing’s disease patients, with reversal of effect upon discontinuation (18, 19, 20). However, this finding was not consistent and cyproheptadine is not effective in EAS. Case 4 was maintained on cyproheptadine by his local physicians. Given the stable dose of cyproheptadine during ACTH fluctuations, it is unlikely that it played a role in inducing remission in this patient.

Case 4 had a history of two previous 6-month episodes of remission and currently has been in remission for 15 months. Underlying tumor cyclicity is the most likely explanation and his case illustrates the importance of differentiating sustained remission from cyclic Cushing’s syndrome. Given previous
reports of recurrent hypercortisolism in cyclic Cushing’s syndrome even after 4 years (6), the possibility of cyclic production of ACTH in cases 2 and 3 cannot be completely excluded. Like case 2, case 3 had no history of cyclicity, and has now been in remission for 5 years, making cyclic Cushing’s syndrome less likely.

In conclusion, long-term treatment with steroidogenesis inhibitors was associated with prolonged periods of remission in these four cases with presumed EAS. However, this may not be a causal relationship. The exact pathophysiology of remission in these cases remains unclear and may involve several possible mechanisms that require further study. While surgical resection of the ectopic tumor remains the optimal treatment, medical treatment with steroidogenesis inhibitors can be used when a source of ACTH cannot be identified. Combined therapy with multiple steroidogenesis inhibitors has been shown to be effective in both rapid and chronic control of hypercortisolism (10, 21). However, optimal control of hypercortisolism is of paramount importance and bilateral adrenalectomy should be considered in cases where this cannot be achieved on medical treatment. Findings from these four cases suggest that ACTH levels should be measured intermittently or medical therapy should be stopped every 1–2 years to assess whether remission has occurred.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This study was supported by the intramural program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.

**References**


Received 2 November 2011 Revised version received 16 December 2011 Accepted 21 December 2011